Coherus Oncology, Inc.
CHRS
$1.13
-$0.045-3.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.25M | 7.60M | 54.14M | 70.77M | 10.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.25M | 7.60M | 54.14M | 70.77M | 10.30M |
| Cost of Revenue | 3.40M | 2.65M | 33.86M | 20.74M | 1.81M |
| Gross Profit | 6.86M | 4.95M | 20.29M | 50.03M | 8.49M |
| SG&A Expenses | 26.04M | 26.03M | 34.60M | 34.74M | 27.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.74M | 53.03M | 89.69M | 77.16M | 49.92M |
| Operating Income | -45.49M | -45.44M | -35.55M | -6.39M | -39.63M |
| Income Before Tax | -44.86M | -47.40M | -50.70M | -10.75M | -54.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.86M | -47.40M | -50.70M | -10.75M | -54.85M |
| Earnings from Discontinued Operations | 342.63M | -9.17M | -- | -- | 41.93M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 297.77M | -56.57M | -50.70M | -10.75M | -12.92M |
| EBIT | -45.49M | -45.44M | -35.55M | -6.39M | -39.63M |
| EBITDA | -44.47M | -44.39M | -34.51M | -4.84M | -38.44M |
| EPS Basic | 2.57 | -0.49 | -0.44 | -0.09 | -0.11 |
| Normalized Basic EPS | -0.24 | -0.26 | -1.19 | -0.06 | -0.23 |
| EPS Diluted | 2.57 | -0.49 | -0.47 | -0.09 | -0.11 |
| Normalized Diluted EPS | -0.24 | -0.26 | -1.19 | -0.06 | -0.23 |
| Average Basic Shares Outstanding | 116.08M | 115.86M | 115.42M | 115.21M | 114.82M |
| Average Diluted Shares Outstanding | 116.08M | 115.86M | 115.42M | 115.21M | 114.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |